Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

BioLineRx (BLRX) Operating Margin (2023 - 2025)

Historic Operating Margin for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to 516.86%.

  • BioLineRx's Operating Margin fell 4078800.0% to 516.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 88.94%, marking a year-over-year increase of 1007400.0%. This contributed to the annual value of 70.52% for FY2024, which is 9647700.0% up from last year.
  • BioLineRx's Operating Margin amounted to 516.86% in Q3 2025, which was down 4078800.0% from 757.57% recorded in Q2 2025.
  • BioLineRx's 5-year Operating Margin high stood at 1405.71% for Q1 2023, and its period low was 1816.63% during Q4 2023.
  • Moreover, its 3-year median value for Operating Margin was 312.92% (2024), whereas its average is 442.34%.
  • The largest annual percentage gain for BioLineRx's Operating Margin in the last 5 years was 17789600bps (2024), contrasted with its biggest fall of -14760600bps (2024).
  • BioLineRx's Operating Margin (Quarter) stood at 1816.63% in 2023, then skyrocketed by 98bps to 37.67% in 2024, then crashed by -1272bps to 516.86% in 2025.
  • Its Operating Margin stands at 516.86% for Q3 2025, versus 757.57% for Q2 2025 and 937.65% for Q1 2025.